Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 11/20 | 0.79 |
| ▸ | ESR1 | P03372 | 3/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | ACP1 | P24666 | 3/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.52 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.50 |
| ▸ | PPARG | P37231 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3820372 | 0.96 | CYP19A1 (0.85) | CYP19A1ESR1KDM4EALDH1A1ACP1 | |
| SCHEMBL3820682 | 0.89 | CYP19A1 (1.00) | CYP19A1ESR1KDM4EALDH1A1ACP1 | |
| SCHEMBL3813556 | 0.88 | CYP19A1 (1.00) | CYP19A1ESR1KDM4EALDH1A1ESR2 | |
| SCHEMBL3817836 | 0.86 | CYP19A1 (1.00) | CYP19A1ESR1KDM4EALDH1A1ACP1 | |
| SCHEMBL15061556 | 0.80 | CYP19A1 (1.00) | CYP19A1ESR1KDM4EALDH1A1 | |
| SCHEMBL3810768 | 0.79 | CYP19A1 (0.86) | CYP19A1KDM4EALDH1A1 | |
| SCHEMBL3816936 | 0.78 | CYP19A1 (0.89) | CYP19A1ALDH1A1 | |
| SCHEMBL2181196 | 0.77 | KDM4E (0.72) | CYP19A1ESR1KDM4EALDH1A1ACP1 | |
| SCHEMBL15061273 | 0.75 | CYP19A1 (1.00) | CYP19A1 | |
| SCHEMBL3813082 | 0.75 | ESR1 (0.67) | CYP19A1ESR1KDM4EALDH1A1ACP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8476313-B2 | Heteroaryl-containing isoflavones as aromatase inhibitors | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2013-07-02 | — | — | US | disclosed |
| US-20090253715-A1 | HETEROARYL-CONTAINING ISOFLAVONES AS AROMATASE INHIBITORS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2009-10-08 | — | — | US | disclosed |
| US-7572919-B2 | 7-Hydroxy-3-(4-hydroxyphenyl)-2-[(phenylmethyl)thio]-4H-1-benzopyran-4-one, for example; reacting deoxybenzoins with a phase transfer catalyst to provide a 2-(alkylthio)isoflavone, deprotecting the 2-(alkylthio)isoflavon, and applying selective debenzylation to form the final compound | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2009-08-11 | — | — | US | disclosed |
| EP-1802599-A2 | HETEROARYL-CONTAINING ISOFLAVONES AS AROMATASE INHIBITORS | The Ohio State University Research Foundation (US) | 2007-07-04 | — | — | EP | disclosed |
| WO-2007001348-A2 | HETEROARYL-CONTAINING ISOFLAVONES AS AROMATASE INHIBITORS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2007-01-04 | — | — | WO | disclosed |
| US-20060183923-A1 | Heteroaryl-containing isoflavones as aromatase inhibitors | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION | 2006-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253715-A1 | HETEROARYL-CONTAINING ISOFLAVONES AS AROMATASE INHIBITORS | CYP19A1, HSD17B11, CYP21A2 | CYP19A1 1/4885ESR1 20/4885KDM4E 1802/4885 |
| US-20060183923-A1 | Heteroaryl-containing isoflavones as aromatase inhibitors | CYP19A1, HSD17B11, CYP21A2 | CYP19A1 1/4885ESR1 20/4885KDM4E 1802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.